THE SECURITIES ACT | ) |
Order No. 5849 |
) |
||
Section 148 | ) |
January 22, 2009 |
Arura Pharma Inc.
WHEREAS:
(A) Arura Pharma Inc. (the "Issuer") is subject to the requirements of Part XII of The Securities Act (Manitoba) (the "Act") and National Instrument 51-102 Continuous Disclosure Obligations (“NI 51-102”);
(B) The Issuer has a financial year end of December 31;
(C) The Issuer has failed to file with The Manitoba Securities Commission (the "Commission") a copy of its Annual Financial Statements and Annual MD&A for the Year ended December 31, 2007 as required by Part XII of the Act and NI 51-102;
(D) On the basis of the foregoing, I am of the opinion that it is in the public interest that trading in the securities of the Issuer should cease forthwith for a period of fifteen days and I am further of the opinion that the holding of a hearing would cause a delay which would be prejudicial to the public interest.
I HEREBY ORDER under a delegation to me by the Commission under subsection 4(1) of the Act of the powers in that behalf:
1. THAT, under sections 147.1(1) and 148(1) of the Act, trading in the securities of the Issuer shall cease forthwith for a period of fifteen days from January 22, 2009 to February 5, 2009, both dates inclusive, or until such earlier date as:
(a) the Issuer becomes current in its filings with the Commission under NI 51-102 and pays all outstanding filing fees, if any, to the Commission; and
(b) the Issuer submits a written application to the Commission in accordance with National Policy 12-202 Revocation of a Compliance-related Cease Trade Order to have this order revoked.
“Bob Bouchard” |